

Deog-Yeon Jo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6351589/publications.pdf>

Version: 2024-02-01

73
papers

776
citations

687363

13
h-index

526287

27
g-index

73
all docs

73
docs citations

73
times ranked

1159
citing authors

#	ARTICLE	IF	CITATIONS
1	Volumetric Splenomegaly in Patients With Polycythemia Vera. <i>Journal of Korean Medical Science</i> , 2022, 37, e87.	2.5	5
2	Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms. <i>Internal Medicine</i> , 2022, 61, 3483-3490.	0.7	2
3	Clinical features and outcomes of hypocellular acute myeloid leukemia in adults. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT₀ /Overlo</i>	1.0	0
4	Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies. <i>Hematology</i> , 2021, 26, 96-102.	1.5	3
5	Volumetric splenomegaly in patients with essential thrombocythemia and prefibrotic/early primary myelofibrosis. <i>International Journal of Hematology</i> , 2021, 114, 35-43.	1.6	5
6	Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3. <i>Leukemia Research</i> , 2021, 105, 106578.	0.8	0
7	Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1190-1203.	1.7	9
8	<i>Helicobacter pylori</i> testing in a population of Korean patients with pernicious anemia. <i>Blood Research</i> , 2020, 55, 69-69.	1.3	0
9	Pulmonary hypertension in patients with Philadelphia-negative myeloproliferative neoplasms: a single-center retrospective analysis of 225 patients. <i>Blood Research</i> , 2020, 55, 77-84.	1.3	3
10	Outcomes of patients with essential thrombocythemia and unnoticed thrombocytosis prior to diagnosis. <i>Blood Research</i> , 2020, 55, 281-282.	1.3	1
11	Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. <i>Annals of Hematology</i> , 2019, 98, 2273-2281.	1.8	2
12	Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 77, 120-128.	1.4	0
13	Retrospective screening for Philadelphia-negative myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 World Health Organization diagnostic criteria. <i>Blood Research</i> , 2019, 54, 284-285.	1.3	3
14	Chronic kidney disease in the BCR-ABL1-negative myeloproliferative neoplasm: a single-center retrospective study. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 790-797.	1.7	15
15	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	1.3	11
16	Low-dose prednisolone in patients with paroxysmal nocturnal hemoglobinuria and inadequate response to eculizumab. <i>Blood Research</i> , 2017, 52, 337.	1.3	2
17	Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party. <i>Oncotarget</i> , 2017, 8, 79414-79424.	1.8	3
18	Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party. <i>Blood Research</i> , 2016, 51, 193.	1.3	6

#	ARTICLE	IF	CITATIONS
19	Two Cases of Intravascular Lymphoma Presenting with Pulmonary Involvement. Journal of Korean Medical Science, 2016, 31, 1011.	2.5	0
20	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. Journal of Korean Medical Science, 2016, 31, 214.	2.5	51
21	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. Annals of Hematology, 2016, 95, 125-133.	1.8	14
22	C-X-C motif receptor 7 in gastrointestinal cancer. Oncology Letters, 2015, 10, 1227-1232.	1.8	4
23	Long-term treatment of residual or recurrent low-grade endometrial stromal sarcoma with aromatase inhibitors: A report of two cases and a review of the literature. Oncology Letters, 2015, 10, 3310-3314.	1.8	23
24	Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells. Blood Research, 2015, 50, 218.	1.3	17
25	Induction of Angiogenesis by Matrigel Coating of VEGF-Loaded PEG/PCL-Based Hydrogel Scaffolds for hBMSC Transplantation. Molecules and Cells, 2015, 38, 663-668.	2.6	11
26	Bortezomib inhibits the survival and proliferation of bone marrow stromal cells. Blood Research, 2015, 50, 87.	1.3	5
27	Just Toxicity, or Toxicity As a Biomarker of Efficacy of Ramucirumab in Breast Cancer?. Journal of Clinical Oncology, 2015, 33, 2712-2712.	1.6	2
28	Sorafenib for patients with differentiated thyroid cancer. Lancet, The, 2015, 385, 228.	13.7	1
29	Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging at Diagnosis in Patients with Multiple Myeloma. Cancer Research and Treatment, 2015, 47, 465-472.	3.0	10
30	Oncologists'™ Experience with Patients with Second Primary Cancer and the Attitudes toward Second Primary Cancer Screening: A Nationwide Survey. Cancer Research and Treatment, 2015, 47, 600-606.	3.0	6
31	Prognostic Implications of Abdominal Computed Tomography at Diagnosis in Patients with Polycythemia Vera or Essential Thrombocythemia. Blood, 2015, 126, 5200-5200.	1.4	0
32	Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry. Blood, 2015, 126, 4789-4789.	1.4	0
33	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. Journal of Korean Medical Science, 2014, 29, 61.	2.5	4
34	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. Blood, 2014, 124, 5151-5151.	1.4	0
35	Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. International Journal of Hematology, 2013, 97, 749-757.	1.6	98
36	Fighting back against chronic myelomonocytic leukemia. Blood Research, 2013, 48, 165.	1.3	0

#	ARTICLE	IF	CITATIONS
37	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. <i>Blood</i> , 2013, 122, 3720-3720.	1.4	1
38	Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1 α . <i>Oncology Reports</i> , 2012, 28, 2239-2246.	2.6	47
39	Diagnostic and Prognostic Implications of Spine Magnetic Resonance Imaging At Diagnosis in Patients with Multiple Myeloma. <i>Blood</i> , 2012, 120, 3999-3999.	1.4	1
40	Clinical Features of Severe Acquired ADAMTS13 Deficiency in Thrombotic Thrombocytopenic Purpura: Second Report of the Korean TTP Registry. <i>Blood</i> , 2012, 120, 2188-2188.	1.4	0
41	Bortezomib Inhibits the Survival and Proliferation of Bone Marrow Stromal Cells Via Downregulation of the Chemokine CXCL12. <i>Blood</i> , 2012, 120, 3951-3951.	1.4	0
42	Risk of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria Presenting with Both Clinical Symptoms and Elevated Hemolysis. <i>Blood</i> , 2012, 120, 1273-1273.	1.4	0
43	CXCR4 antagonists in hematologic malignancies: more than just mobilizers?. <i>The Korean Journal of Hematology</i> , 2011, 46, 209.	0.7	1
44	Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2011, 118, 3166-3166.	1.4	7
45	Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study. <i>Blood</i> , 2011, 118, 3424-3424.	1.4	0
46	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. <i>Blood</i> , 2011, 118, 1866-1866.	1.4	0
47	Hepatic Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acquired Aplastic Anemia. <i>Blood</i> , 2011, 118, 3012-3012.	1.4	0
48	Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2011, 118, 5273-5273.	1.4	0
49	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. <i>International Journal of Hematology</i> , 2010, 92, 52-57.	1.6	41
50	Association Between Elevated Hemolysis at Diagnosis and Early Mortality and Risk of Thrombosis In Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients with Cytopenia. <i>Blood</i> , 2010, 116, 4241-4241.	1.4	4
51	Prognostic Factors on Survival After Hematopoietic Stem Cell Transplantation for Adult Over 40 Years In Aplastic Anemia. <i>Blood</i> , 2010, 116, 1315-1315.	1.4	0
52	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox In Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 mri. <i>Blood</i> , 2010, 116, 1125-1125.	1.4	0
53	A Case of Multiple Myeloma Associated with Multifocal Osteosclerosis (Multiple Myeloma with) Tj ETQq1 1 0.784314 rgBT /Overlock 10 0.7 2	0.7	2
54	Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry. <i>Acta Haematologica</i> , 2009, 122, 200-210.	1.4	28

#	ARTICLE	IF	CITATIONS
55	Dexamethasone and hypoxia upregulate CXCR4 expression in myeloma cells. <i>Leukemia and Lymphoma</i> , 2009, 50, 1163-1173.	1.3	20
56	Improved Survival of Patients with Multiple Myeloma and the Impact of Transplantation and Novel Agents: An Analysis of the Korean Multiple Myeloma Working Party (KMMWP).. <i>Blood</i> , 2009, 114, 4881-4881.	1.4	0
57	The CXCR4 Antagonist AMD3100 Has Dual Effects, Initially Enhancing and Later Inhibiting Survival and Proliferation, in Myeloid Leukemia Cells in Vitro.. <i>Blood</i> , 2009, 114, 1721-1721.	1.4	0
58	A Case of Central Nervous System Myelomatosis Developing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>The Korean Journal of Hematology</i> , 2008, 43, 194.	0.7	2
59	The CXCR4 Antagonist AMD3100 Stimulates the Proliferation of Myeloma Cells.. <i>Blood</i> , 2008, 112, 1701-1701.	1.4	1
60	GST T1 and GST M1 Polymorphisms Are Associated with the Risk of Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3978-3978.	1.4	0
61	A Case of Limbic Encephalitis Developed after Allogeneic Stem Cell Transplantation. <i>The Korean Journal of Hematology</i> , 2006, 41, 297.	0.7	0
62	A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma. <i>International Journal of Hematology</i> , 2006, 83, 309-313.	1.6	32
63	Interferon β Has Dual Potential in Inhibiting or Promoting Survival and Growth of Hematopoietic Progenitors: Interactions with Stromal Cell-Derived Factor 1. <i>International Journal of Hematology</i> , 2006, 84, 143-150.	1.6	8
64	Overexpression of Stromal Cell-derived Factor-1 Enhances Endothelium-supported Transmigration, Maintenance, and Proliferation of Hematopoietic Progenitor Cells. <i>Stem Cells and Development</i> , 2006, 15, 260-268.	2.1	18
65	Association of cis-Acting rs530 of the ETS2 Transcriptional Factor Gene with High-Risk Acute Myelogenous Leukemia (AML) and Allelic Expression Imbalance Assessment.. <i>Blood</i> , 2006, 108, 2230-2230.	1.4	0
66	A Case of Soft Tissue Bleeding Due to a Possible Drug Interaction between Warfarin and TS-1. <i>The Korean Journal of Hematology</i> , 2005, 40, 271.	0.7	0
67	Pernicious Anemia: A Retrospective Analysis of 22 Cases. <i>The Korean Journal of Hematology</i> , 2005, 40, 219.	0.7	3
68	Over-Expression of Stromal Cell-Derived Factor-1 in Non-Specialized Endothelium Enhances the Endothelium-Supported Transmigration, Maintenance, and Proliferation of Hematopoietic Progenitor Cells.. <i>Blood</i> , 2005, 106, 2299-2299.	1.4	0
69	Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.. <i>Blood</i> , 2005, 106, 3500-3500.	1.4	0
70	Dexamethasone Down-Regulates Stromal Cell-Derived Factor-1 Production in Bone Marrow Stromal Cells: Implications in Myeloma Cell Biology.. <i>Blood</i> , 2005, 106, 2510-2510.	1.4	0
71	Direct and Indirect Effects of Oxymetholone on Growth and Apoptosis of Hematopoietic Progenitor Cells In Vitro.. <i>Blood</i> , 2004, 104, 4127-4127.	1.4	0
72	Human bone marrow endothelial cells elaborate non-stromal cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors. <i>British Journal of Haematology</i> , 2003, 121, 649-652.	2.5	18

#	ARTICLE	IF	CITATIONS
73	Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. Journal of Clinical Investigation, 2000, 105, 101-111.	8.2	226